Outlook Therapeutics/$OTLK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Outlook Therapeutics
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Ticker
$OTLK
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
23
ISIN
US69012T3059
Website
OTLK Metrics
BasicAdvanced
$77M
2.17
$0.83
0.39
-
Price and volume
Market cap
$77M
Beta
0.39
52-week high
$9.25
52-week low
$0.87
Average daily volume
820K
Financial strength
Current ratio
0.717
Quick ratio
0.304
Long term debt to equity
-65.503
Total debt to equity
-102.636
Interest coverage (TTM)
-292.19%
Profitability
EBITDA (TTM)
-76.323
Effective tax rate (TTM)
0.01%
Management effectiveness
Return on assets (TTM)
-122.33%
Return on equity (TTM)
-25.34%
Valuation
Price to earnings (TTM)
2.172
Price to book
-1.82
Price to tangible book (TTM)
-1.82
Price to free cash flow (TTM)
-0.716
Free cash flow yield (TTM)
-139.60%
Free cash flow per share (TTM)
-251.27%
Growth
Earnings per share change (TTM)
-106.92%
3-year earnings per share growth (CAGR)
-49.45%
What the Analysts think about OTLK
Analyst ratings (Buy, Hold, Sell) for Outlook Therapeutics stock.
OTLK Financial Performance
Revenues and expenses
OTLK Earnings Performance
Company profitability
OTLK News
AllArticlesVideos
Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event
GlobeNewsWire·1 week ago
Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
GlobeNewsWire·2 weeks ago
Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Outlook Therapeutics stock?
Outlook Therapeutics (OTLK) has a market cap of $77M as of June 26, 2025.
What is the P/E ratio for Outlook Therapeutics stock?
The price to earnings (P/E) ratio for Outlook Therapeutics (OTLK) stock is 2.17 as of June 26, 2025.
Does Outlook Therapeutics stock pay dividends?
No, Outlook Therapeutics (OTLK) stock does not pay dividends to its shareholders as of June 26, 2025.
When is the next Outlook Therapeutics dividend payment date?
Outlook Therapeutics (OTLK) stock does not pay dividends to its shareholders.
What is the beta indicator for Outlook Therapeutics?
Outlook Therapeutics (OTLK) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.